Compare · BRTX vs CSLT
BRTX vs CSLT
Side-by-side comparison of BioRestorative Therapies Inc. (BRTX) and Castlight Health Inc. (CSLT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRTX and CSLT operate in Managed Health Care (Health Care), so they compete in similar markets.
- CSLT is the larger of the two at $285.2M, about 27.6x BRTX ($10.3M).
- BRTX has hit the wire 3 times in the past 4 weeks while CSLT has been quiet.
- BRTX has more recent analyst coverage (1 ratings vs 0 for CSLT).
- Company
- BioRestorative Therapies Inc.
- Castlight Health Inc.
- Price
- -
- -
- Market cap
- $10.3M
- $285.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Managed Health Care
- Managed Health Care
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 3
- 0
- Recent ratings
- 1
- 0
BioRestorative Therapies Inc.
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100 that has completed Phase 1 clinical trials is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate, which is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue (BAT). In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
Castlight Health Inc.
Castlight Health, Inc. provides health navigation solutions for employers and health plan customers in education, manufacturing, retail, government, and technology industries in the United States. It provides Care Guidance Navigator that enables users to make better care decisions and navigate the employer-sponsored healthcare benefit programs; Wellbeing Navigator, which helps to drive engagement across an employer's benefits program; Complete Health Navigator that combines the Wellbeing Navigator and Care Guidance Navigator packages for unified user experience; and Castlight Care Guides, a high-touch navigation service. The company also offers white-labeled health navigation solutions and embedded platform technology services. In addition, it provides implementation and marketplace services. The company was formerly known as Ventana Health Services and changed its name to Castlight Health, Inc. in April 2010. Castlight Health, Inc. was incorporated in 2008 and is headquartered in San Francisco, California.
Latest BRTX
- BioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
- BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
- SEC Form 10-Q filed by BioRestorative Therapies Inc.
- BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals
- BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease
- BioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 424B3 filed by BioRestorative Therapies Inc.
- BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform
- SEC Form EFFECT filed by BioRestorative Therapies Inc.
Latest CSLT
- Castlight Health, Now Part of apree health, Adds Six Digital Health Partners and New Pharmacy Savings Category to its Ecosystem
- Castlight Health Selected to Enable New Capabilities for Blue Cross and Blue Shield of Minnesota
- Castlight's Workforce Health Index Details the Adverse Health Effects of Delayed Care Due to COVID-19
- SEC Form 15-12B filed by Castlight Health Inc.
- Castlight Health Announces Illuminate 2022: Workforce Health, Reimagined
- SEC Form 4: Verhave Judith K. returned 351,516 units of Class B Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Van Zant Kenny returned 661,794 units of Class B Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Roberts Bryan E returned 5,660,448 units of Class B Common Stock to the company
- SEC Form 4: Venrock Associates V Lp returned 5,255,264 units of Class B Common Stock to the company
- SEC Form 4: Singer David B returned 405,184 units of Class B Common Stock to the company, closing all direct ownership in the company